Edison Investment Research - iCo Therapeutics Inc. (ICO.) QuickView: Moving forward with OralAmpB

Report

Edison Investment Research

QuickView: Moving forward with OralAmpB

iCo is deploying C$0.7m in grant funding to move ahead with preclinical development of its proprietary oral formulation of well-established anti-fungal amphotericin B (AmpB). OralAmpB holds potential promise in HIV reservoir treatment, as well as more conventional anti-fungal and parasitic diseases, with a Phase Ia trial expected to start in Q116.

12/11/2014 2 EN

Underlying

iCo Therapeutics Inc.

iCo Therapeutics is a biotechnology company principally focused on the identification, development and commercilization of drug candidates with a clinical history and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Co. has in-licensed three assets: iCo-007; iCo-008 and the Oral AmpB Delivery System.

See profile

CA45107J1057 TSX Venture Exchange Canada

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Newsfile Corp.

Satellos Bioscience Announces Partnership with Jesse's Journey

Toronto, Ontario--(Newsfile Corp. - September 7, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), and Jesse's Journey, Canada's leader in Duchenne muscular dystrophy funded research, are proud to announce a research partnership and infrastructure grant to support the development of Satellos' novel approach to treating Duchenne.Satellos scientists are developing small molecule drugs that they believe will restore faulty regeneration and repair observed in the muscles of patients with Duchenne and potentially other degenerative muscle disorders. The company's drug candidates regulate...

September 7, 2021 September 7, 2021 1 EN

Newsfile Corp.

Satellos Bioscience Announces Second Quarter 2021 Financial Results and MD&A

Toronto, Ontario--(Newsfile Corp. - August 30, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), formerly iCo Therapeutics Inc. ("iCo"), today filed financial results and MD&A reports for the second quarter which ended on June 30, 2021, on SEDAR. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards.Satellos is developing small molecule drugs that restore faulty regeneration and repair observed in the muscles of patients with Duchenne muscular dystrophy and potentially other degenerative muscle disorders...

August 30, 2021 August 30, 2021 1 EN

Newsfile Corp.

Satellos Bioscience Announces High Resolution Crystal Structure of Duchenne Drug Target

Toronto, Ontario--(Newsfile Corp. - August 27, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos") announced today that they have successfully determined a high resolution (1.85Å) X-ray crystal structure of their novel drug target for Duchenne muscular dystrophy ("Duchenne").Satellos scientists are developing small molecule drugs that restore faulty regeneration and repair observed in the muscles of patients with Duchenne and potentially other degenerative muscle disorders. The company's drug candidates regulate the activity of PTP-X, the codename for an enzyme which Satellos discovere...

August 27, 2021 August 27, 2021 1 EN

Norcros - Sale of Johnson Tiles UK agreed

Norcros’s disposal of Johnson Tiles is the latest strategic activity taken by management to better allocate capital to fit with priorities. Last year it closed its UK adhesives operation. Norcros has a compelling investment case, where its new product development initiatives, market positioning and self-help initiatives allow it to take market share in both the UK and South Africa. Its rating is low at 6.0x FY24e P/E, which is attractive, especially when compared to its yield of 5.4% on its well-covered dividend. We retain our estimates and value the shares at 246p, implying c 30% upside.

16h / 17m 16h / 17m 1 EN

Pedro Fonseca

Pedro Fonseca

Henderson Far East Income - Repositioning to raise total returns

Henderson Far East Income (HFEL) has consistently delivered on its objective to provide a rising dividend. However, like many investors, HFEL’s managers overestimated the potential for a post-pandemic rebound in China. The trust’s resultant overweight to Chinese consumer and other cyclicals led to a fall in portfolio revenues and underperformance in the financial year ended 31 August 2023 (FY23). With a view to improving future returns, HFEL’s board has since indicated an increased willingness to use reserves when necessary to support dividend payments, which it did in FY23. This reduces the r...

19h / 7m 19h / 7m 1 EN

Richard Williamson

Richard Williamson

Freelancer - AI to drive return to growth

Freelancer’s Q124 results were mixed. Operationally, the company is seeing rising demand for AI specialists as customers seek affordable ways to develop proprietary AI. Notably, in Enterprise, the company delivered a large-scale AI pilot for a tech giant, sourcing 20,000 freelancers in 24 hours across 52 languages. This impressive achievement could lead to a substantial multi-year contract. Major initiatives across Loadshift and Escrow with leading organisations are set to be deployed over the coming months, potentially catalysing performance and diversifying revenue streams. We revise our for...

20h / 9m 20h / 9m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: Moving forward with OralAmpB

Satellos Bioscience Announces Partnership with Jesse's Journey

Satellos Bioscience Announces Second Quarter 2021 Financial Results and MD&A

Satellos Bioscience Announces High Resolution Crystal Structure of Duchenne Drug Target

Norcros - Sale of Johnson Tiles UK agreed

Henderson Far East Income - Repositioning to raise total returns

Freelancer - AI to drive return to growth

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe